کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5503455 | 1535286 | 2017 | 36 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
سالمندی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Discontinuation of bisphosphonates should be considered in all patients who have been treated for more than five years with alendronate, risedronate or zoledronic acid. In view of the limited evidence, no robust recommendations can be made for ibandronate and denosumab. If the patient has not experienced fractures before or during therapy and the fracture risk is low, a “drug holiday” can be recommended. Although there is no solid evidence, 1-2 years for risedronate, 3-5 years for alendronate and 3-6 years for zoledronic acid are suggested. After this time, the patient should be reassessed. If a new fracture is experienced, or fracture risk has increased or BMD remains low (femoral neck T-score â¤â2.5), anti-osteoporotic treatment should be resumed. In the case of denosumab discontinuation, close monitoring is suggested, due to the possibility of rebound fractures.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Maturitas - Volume 101, July 2017, Pages 23-30
Journal: Maturitas - Volume 101, July 2017, Pages 23-30
نویسندگان
Panagiotis Anagnostis, Stavroula A. Paschou, Gesthimani Mintziori, Iuliana Ceausu, Herman Depypere, Irene Lambrinoudaki, Alfred Mueck, Faustino R. Pérez-López, Margaret Rees, Levent M. Senturk, Tommaso Simoncini, John C. Stevenson, Petra Stute,